Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine.

Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, Kindler L, Flack RS, Wu W, Anderson B, Zhai Y, Yuan XJ, Pogue M, Van Horn RD, Rao X, McCann D, Dropsey AJ, Manro J, Walgren J, Yuen E, Rodriguez MJ, Plowman GD, Tiu RV, Joseph S, Peng SB.

Mol Cancer Ther. 2019 Nov 19. pii: molcanther.0183.2019. doi: 10.1158/1535-7163.MCT-19-0183. [Epub ahead of print]

PMID:
31744895
2.

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17.

PMID:
31530649
3.

Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.

Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, Chio LC, Van Horn RD, Lin X, Blosser W, Han B, Jin S, Yao S, Bian H, Ficklin C, Fan L, Kapoor A, Antonysamy S, Mc Nulty AM, Froning K, Manglicmot D, Pustilnik A, Weichert K, Wasserman SR, Dowless M, Marugán C, Baquero C, Lallena MJ, Eastman SW, Hui YH, Dieter MZ, Doman T, Chu S, Qian HR, Ye XS, Barda DA, Plowman GD, Reinhard C, Campbell RM, Henry JR, Buchanan SG.

Cancer Discov. 2019 Feb;9(2):248-263. doi: 10.1158/2159-8290.CD-18-0469. Epub 2018 Oct 29.

PMID:
30373917
4.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE.

J Immunother Cancer. 2018 Jun 4;6(1):47. doi: 10.1186/s40425-018-0356-4.

5.

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.

Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.

Clin Cancer Res. 2017 Sep 15;23(18):5547-5560. doi: 10.1158/1078-0432.CCR-16-3250. Epub 2017 Jun 13.

6.

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB.

Cancer Discov. 2016 Mar;6(3):300-15. doi: 10.1158/2159-8290.CD-15-0896. Epub 2016 Jan 5.

7.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.

Cancer Cell. 2015 Sep 14;28(3):384-98. doi: 10.1016/j.ccell.2015.08.002. Epub 2015 Sep 3.

8.

Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung.

Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, Ackermann BL, Konrad RJ, Nasir A.

PLoS One. 2013 Nov 14;8(11):e80292. doi: 10.1371/journal.pone.0080292. eCollection 2013.

9.

A comparison of least squares and conditional maximum likelihood estimators under volume endpoint censoring in tumor growth experiments.

Roy Choudhury K, O'Sullivan F, Kasman I, Plowman GD.

Stat Med. 2012 Dec 20;31(29):4061-73. doi: 10.1002/sim.5507. Epub 2012 Jul 24.

PMID:
22826185
10.

Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models.

Roy Choudhury K, Kasman I, Plowman GD.

Stat Med. 2010 Oct 15;29(23):2399-409. doi: 10.1002/sim.3992.

PMID:
20564736
11.

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.

Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh G, Hollister B, Rosen O, Plowman GD.

Clin Cancer Res. 2010 Aug 1;16(15):3887-900. doi: 10.1158/1078-0432.CCR-09-3100. Epub 2010 Jun 16.

12.

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.

Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC, Cao TC, Lee CV, Nannini MA, Fuh G, Carano RA, Koeppen H, Yu RX, Forrest WF, Plowman GD, Johnson L.

Nat Biotechnol. 2010 Jun;28(6):585-93. doi: 10.1038/nbt.1640. Epub 2010 May 23.

PMID:
20495549
13.

Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale.

Bagri A, Kouros-Mehr H, Leong KG, Plowman GD.

Trends Mol Med. 2010 Mar;16(3):122-32. doi: 10.1016/j.molmed.2010.01.004. Epub 2010 Feb 26. Review.

PMID:
20189876
14.

Chronic DLL4 blockade induces vascular neoplasms.

Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD.

Nature. 2010 Feb 11;463(7282):E6-7. doi: 10.1038/nature08751.

PMID:
20147986
15.

Delta-like 4/Notch signaling and its therapeutic implications.

Yan M, Plowman GD.

Clin Cancer Res. 2007 Dec 15;13(24):7243-6. Review.

16.

Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene.

Edgar KA, Belvin M, Parks AL, Whittaker K, Mahoney MB, Nicoll M, Park CC, Winter CG, Chen F, Lickteig K, Ahmad F, Esengil H, Lorenzi MV, Norton A, Rupnow BA, Shayesteh L, Tabios M, Young LM, Carroll PM, Kopczynski C, Plowman GD, Friedman LS, Francis-Lang HL.

Genetics. 2005 May;170(1):161-71. Epub 2005 Mar 2.

17.

Overcoming the gridlock in discovery research.

Margolis J, Plowman GD.

Nat Biotechnol. 2004 May;22(5):522-4. No abstract available.

PMID:
15122288
18.

Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome.

Parks AL, Cook KR, Belvin M, Dompe NA, Fawcett R, Huppert K, Tan LR, Winter CG, Bogart KP, Deal JE, Deal-Herr ME, Grant D, Marcinko M, Miyazaki WY, Robertson S, Shaw KJ, Tabios M, Vysotskaia V, Zhao L, Andrade RS, Edgar KA, Howie E, Killpack K, Milash B, Norton A, Thao D, Whittaker K, Winner MA, Friedman L, Margolis J, Singer MA, Kopczynski C, Curtis D, Kaufman TC, Plowman GD, Duyk G, Francis-Lang HL.

Nat Genet. 2004 Mar;36(3):288-92. Epub 2004 Feb 22.

19.

Evolution of protein kinase signaling from yeast to man.

Manning G, Plowman GD, Hunter T, Sudarsanam S.

Trends Biochem Sci. 2002 Oct;27(10):514-20. Review.

PMID:
12368087
20.

Informatics issues in large-scale sequence analysis: elucidating the protein kinases of C. elegans.

Bingham J, Plowman GD, Sudarsanam S.

J Cell Biochem. 2000 Oct 20;80(2):181-6.

PMID:
11074585
21.

The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms.

Plowman GD, Sudarsanam S, Bingham J, Whyte D, Hunter T.

Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13603-10. Review.

22.

Neuregulins signaling via a glial erbB-2-erbB-4 receptor complex contribute to the neuroendocrine control of mammalian sexual development.

Ma YJ, Hill DF, Creswick KE, Costa ME, Cornea A, Lioubin MN, Plowman GD, Ojeda SR.

J Neurosci. 1999 Nov 15;19(22):9913-27.

23.

The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis.

Bischoff JR, Plowman GD.

Trends Cell Biol. 1999 Nov;9(11):454-9. Review.

PMID:
10511710
24.

The discovery and validation of new drug targets in cancer.

Courtneidge SA, Plowman GD.

Curr Opin Biotechnol. 1998 Dec;9(6):632-6. Review.

PMID:
9889138
25.
26.

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers.

Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD.

EMBO J. 1998 Jun 1;17(11):3052-65.

27.

Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2.

Riese DJ 2nd, Komurasaki T, Plowman GD, Stern DF.

J Biol Chem. 1998 May 1;273(18):11288-94.

28.

Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype.

Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR, Pittelkow MR.

J Clin Invest. 1997 Nov 1;100(9):2286-94.

30.

A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester.

Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, Klagsbrun M.

J Biol Chem. 1997 Oct 17;272(42):26761-8.

31.

Close similarity between Drosophila neurexin IV and mammalian Caspr protein suggests a conserved mechanism for cellular interactions.

Peles E, Joho K, Plowman GD, Schlessinger J.

Cell. 1997 Mar 21;88(6):745-6. No abstract available.

32.

Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions.

Peles E, Nativ M, Lustig M, Grumet M, Schilling J, Martinez R, Plowman GD, Schlessinger J.

EMBO J. 1997 Mar 3;16(5):978-88.

33.

The protein kinases of budding yeast: six score and more.

Hunter T, Plowman GD.

Trends Biochem Sci. 1997 Jan;22(1):18-22. Review.

PMID:
9020587
34.
35.
36.

Amphiregulin in lung branching morphogenesis: interaction with heparan sulfate proteoglycan modulates cell proliferation.

Schuger L, Johnson GR, Gilbride K, Plowman GD, Mandel R.

Development. 1996 Jun;122(6):1759-67.

37.
38.

Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family.

Mossie K, Jallal B, Alves F, Sures I, Plowman GD, Ullrich A.

Oncogene. 1995 Nov 16;11(10):2179-84.

PMID:
7478540
39.

The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Riese DJ 2nd, van Raaij TM, Plowman GD, Andrews GC, Stern DF.

Mol Cell Biol. 1995 Oct;15(10):5770-6. Erratum in: Mol Cell Biol 1996 Feb;16(2):735.

40.

Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines.

Martínez-Lacaci I, Saceda M, Plowman GD, Johnson GR, Normanno N, Salomon DS, Dickson RB.

Endocrinology. 1995 Sep;136(9):3983-92.

PMID:
7649107
41.

Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions.

Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B, Schlessinger J.

Nature. 1995 Aug 31;376(6543):737-45.

PMID:
7544443
42.

The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin.

Peles E, Nativ M, Campbell PL, Sakurai T, Martinez R, Lev S, Clary DO, Schilling J, Barnea G, Plowman GD, Grumet M, Schlessinger J.

Cell. 1995 Jul 28;82(2):251-60.

43.

Mouse chromosomal location of three EGF receptor ligands: amphiregulin (Areg), betacellulin (Btc), and heparin-binding EGF (Hegfl).

Pathak BG, Gilbert DJ, Harrison CA, Luetteke NC, Chen X, Klagsbrun M, Plowman GD, Copeland NG, Jenkins NA, Lee DC.

Genomics. 1995 Jul 1;28(1):116-8.

PMID:
7590736
44.

Induction of autocrine epidermal growth factor receptor ligands in human keratinocytes by insulin/insulin-like growth factor-1.

Vardy DA, Kari C, Lazarus GS, Jensen PJ, Zilberstein A, Plowman GD, Rodeck U.

J Cell Physiol. 1995 May;163(2):257-65.

PMID:
7706370
46.

HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein.

Siegall CB, Bacus SS, Cohen BD, Plowman GD, Mixan B, Chace D, Chin DM, Goetze A, Green JM, Hellström I, et al.

J Biol Chem. 1995 Mar 31;270(13):7625-30.

48.
49.

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4.

Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S.

Nature. 1993 Dec 2;366(6454):473-5.

PMID:
7902537
50.

Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor.

Culouscou JM, Plowman GD, Carlton GW, Green JM, Shoyab M.

J Biol Chem. 1993 Sep 5;268(25):18407-10.

Supplemental Content

Loading ...
Support Center